These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33180377)

  • 1. Suppression of malignant rhabdoid tumors through Chb-M'-mediated RUNX1 inhibition.
    Daifu T; Mikami M; Hiramatsu H; Iwai A; Umeda K; Noura M; Kubota H; Masuda T; Furuichi K; Takasaki S; Noguchi Y; Morita K; Bando T; Hirata M; Kataoka TR; Nakahata T; Kuwahara Y; Iehara T; Hosoi H; Takita J; Sugiyama H; Adachi S; Kamikubo Y
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28789. PubMed ID: 33180377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.
    Mikami M; Masuda T; Kanatani T; Noura M; Umeda K; Hiramatsu H; Kubota H; Daifu T; Iwai A; Hattori EY; Furuichi K; Takasaki S; Tanaka S; Matsui Y; Matsuo H; Hirata M; Kataoka TR; Nakahata T; Kuwahara Y; Iehara T; Hosoi H; Imai Y; Takita J; Sugiyama H; Adachi S; Kamikubo Y
    Mol Cells; 2022 Dec; 45(12):886-895. PubMed ID: 36572559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chlorambucil-conjugated PI-polyamides (Chb-M'), a transcription inhibitor of RUNX family, has an anti-tumor activity against SHH-type medulloblastoma with p53 mutation.
    Matsui Y; Mineharu Y; Noguchi Y; Hattori EY; Kubota H; Hirata M; Miyamoto S; Sugiyama H; Arakawa Y; Kamikubo Y
    Biochem Biophys Res Commun; 2022 Sep; 620():150-157. PubMed ID: 35792512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic regulation of the RUNX transcription factor family has antitumor effects.
    Morita K; Suzuki K; Maeda S; Matsuo A; Mitsuda Y; Tokushige C; Kashiwazaki G; Taniguchi J; Maeda R; Noura M; Hirata M; Kataoka T; Yano A; Yamada Y; Kiyose H; Tokumasu M; Matsuo H; Tanaka S; Okuno Y; Muto M; Naka K; Ito K; Kitamura T; Kaneda Y; Liu PP; Bando T; Adachi S; Sugiyama H; Kamikubo Y
    J Clin Invest; 2017 Jun; 127(7):2815-2828. PubMed ID: 28530640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
    Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
    Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.
    Shibui Y; Kohashi K; Tamaki A; Kinoshita I; Yamada Y; Yamamoto H; Taguchi T; Oda Y
    J Cancer Res Clin Oncol; 2021 May; 147(5):1499-1518. PubMed ID: 33221995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
    Darr J; Klochendler A; Isaac S; Eden A
    Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor.
    Nodomi S; Umeda K; Saida S; Kinehara T; Hamabata T; Daifu T; Kato I; Hiramatsu H; Watanabe KI; Kuwahara Y; Iehara T; Adachi S; Konishi E; Nakahata T; Hosoi H; Heike T
    Oncogene; 2016 Oct; 35(40):5317-5327. PubMed ID: 27041577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapeutic targets for the treatment of malignant rhabdoid tumors.
    Nemes K; Frühwald MC
    Expert Opin Ther Targets; 2018 Apr; 22(4):365-379. PubMed ID: 29528755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Evaluation of Combined Targeted Approaches in Malignant Rhabdoid Tumors.
    Moreno N; Kerl K
    Anticancer Res; 2016 Aug; 36(8):3883-7. PubMed ID: 27466490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors.
    Calandrini C; van Hooff SR; Paassen I; Ayyildiz D; Derakhshan S; Dolman MEM; Langenberg KPS; van de Ven M; de Heus C; Liv N; Kool M; de Krijger RR; Tytgat GAM; van den Heuvel-Eibrink MM; Molenaar JJ; Drost J
    Cell Rep; 2021 Aug; 36(8):109568. PubMed ID: 34433038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo.
    Kuwahara Y; Hosoi H; Osone S; Kita M; Iehara T; Kuroda H; Sugimoto T
    Clin Cancer Res; 2004 Sep; 10(17):5940-8. PubMed ID: 15355927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1.
    Kerl K; Moreno N; Holsten T; Ahlfeld J; Mertins J; Hotfilder M; Kool M; Bartelheim K; Schleicher S; Handgretinger R; Schüller U; Meisterernst M; Frühwald MC
    Int J Cancer; 2014 Aug; 135(4):989-95. PubMed ID: 24420698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
    Muscat A; Popovski D; Jayasekara WS; Rossello FJ; Ferguson M; Marini KD; Alamgeer M; Algar EM; Downie P; Watkins DN; Cain JE; Ashley DM
    Clin Cancer Res; 2016 Jul; 22(14):3560-70. PubMed ID: 26920892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient.
    Kuwahara Y; Iehara T; Ichise E; Katsumi Y; Ouchi K; Tsuchiya K; Miyachi M; Konishi E; Sasajima H; Nakamura S; Fumino S; Tajiri T; Johann PD; FrÜhwald MC; Yoshida T; Okuda T; Hosoi H
    Anticancer Res; 2020 Nov; 40(11):6159-6170. PubMed ID: 33109553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
    Darr J; Klochendler A; Isaac S; Geiger T; Eden A
    Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant rhabdoid tumor of the liver presented with initial tumor rupture.
    Kachanov D; Teleshova M; Kim E; Dobrenkov K; Moiseenko R; Usychkina A; Filin A; Semenkov A; Mitrofanova A; Konovalov D; Shamanskaya T; Novichkova G; Varfolomeeva S
    Cancer Genet; 2014 Sep; 207(9):412-4. PubMed ID: 24894493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.
    Schanda J; Lee CW; Wohlan K; Müller-Kuller U; Kunkel H; Coco IQ; Stein S; Metz A; Koch J; Lausen J; Platzbecker U; Medyouf H; Gohlke H; Heuser M; Eder M; Grez M; Scherr M; Wichmann C
    Haematologica; 2017 May; 102(5):e170-e174. PubMed ID: 28154087
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.